Education
About Us
Working with TipRanks
Follow Us
Gilead Sciences (CH:GILD)
:GILD
Total Valuation
Gilead Sciences has a market cap or net worth of $123.32B. The enterprise value is ―.
Market Cap$123.32B
Enterprise Value―
Share Statistics
Gilead Sciences has 1,240,806,900 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding1,240,806,900
Owned by Insiders0.09%
Owned by Institutions1.58%
Financial Efficiency
Gilead Sciences’s return on equity (ROE) is 0.02 and return on invested capital (ROIC) is 2.36%.
Return on Equity (ROE)0.02
Return on Assets (ROA)<0.01
Return on Invested Capital (ROIC)2.36%
Return on Capital Employed (ROCE)0.04
Revenue Per Employee1.63M
Profits Per Employee27.27K
Employee Count17,600
Asset Turnover0.49
Inventory Turnover3.66
Valuation Ratios
The current PE Ratio of Gilead Sciences is 13.1. Gilead Sciences’s PEG ratio is -2.62.
PE Ratio13.1
PS Ratio4.01
PB Ratio5.96
Price to Fair Value5.96
Price to FCF11.18
Price to Operating Cash Flow15.28
PEG Ratio-2.62
Income Statement
In the last 12 months, Gilead Sciences had revenue of 28.75B and earned 480.00M in profits. Earnings per share was 0.38.
Revenue28.75B
Gross Profit22.50B
Operating Income1.66B
Pretax Income690.00M
Net Income480.00M
EBITDA4.43B
Earnings Per Share (EPS)0.38
Cash Flow
In the last 12 months, operating cash flow was 9.67B and capital expenditures -147.00M, giving a free cash flow of 9.52B billion.
Operating Cash Flow9.67B
Free Cash Flow9.52B
Free Cash Flow per Share7.67
Dividends & Yields
Gilead Sciences pays an annual dividend of CHF0.71, resulting in a dividend yield of 2.79%
Dividend Per ShareCHF0.71
Dividend Yield2.79%
Payout Ratio78.17%
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta―
52-Week Price Change0.00%
50-Day Moving Average67.87
200-Day Moving Average67.87
Relative Strength Index (RSI)100.00
Average Volume (3m)0.00
Important Dates
Gilead Sciences upcoming earnings date is Feb 10, 2026, After Close (Confirmed).
Last Earnings DateOct 30, 2025
Next Earnings DateFeb 10, 2026
Ex-Dividend DateMar 12, 2021
Financial Position
Gilead Sciences as a current ratio of 1.60, with Debt / Equity ratio of 13.08%
Current Ratio1.60
Quick Ratio1.45
Debt to Market Cap0.23
Net Debt to EBITDA3.77
Interest Coverage Ratio1.70
Taxes
In the past 12 months, Gilead Sciences has paid 211.00M in taxes.
Income Tax211.00M
Effective Tax Rate0.31
Enterprise Valuation
Gilead Sciences EV to EBITDA ratio is 29.75, with an EV/FCF ratio of 12.80.
EV to Sales4.59
EV to EBITDA29.75
EV to Free Cash Flow12.80
EV to Operating Cash Flow12.18
Balance Sheet
Gilead Sciences has $9.35B in cash and marketable securities with $2.81B in debt, giving a net cash position of $6.55B billion.
Cash & Marketable Securities$9.35B
Total Debt$2.81B
Net Cash$6.55B
Net Cash Per Share$5.28
Tangible Book Value Per Share-$7.23
Margins
Gross margin is 78.71%, with operating margin of 5.78%, and net profit margin of 1.67%.
Gross Margin78.71%
Operating Margin5.78%
Pretax Margin2.40%
Net Profit Margin1.67%
EBITDA Margin15.42%
EBIT Margin5.80%
Analyst Forecast
The average price target for Gilead Sciences is $106.79, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$106.79
Price Target Upside57.35% Upside
Analyst ConsensusStrong Buy
Analyst Count21
Revenue Growth Forecast―
EPS Growth Forecast―